The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ABBVIE INC. COM 00287Y109 75 1,000 SH   SOLE   1,000 0 0
ALLERGAN PLC SHS G0177J108 175,442 1,042,500 SH   SOLE   1,042,500 0 0
BIOGEN INC. COM 09062X103 149,703 643,000 SH   SOLE   643,000 0 0
INNOVIVA INC. COM 45781M101 65,790 6,242,000 SH   SOLE   6,242,000 0 0
INTERCEPT PHARMACEUTICALS INC. COM 45845P108 56,472 851,000 SH   SOLE   851,000 0 0
IRONWOOD PHARMACEUTICALS INC. COM CL A 46333X108 86,734 10,103,000 SH   SOLE   10,103,000 0 0
JAZZ PHARMACEUTICALS PLC SHS USD G50871105 31,009 242,000 SH   SOLE   242,000 0 0
MEDICINES CO. COM 584688105 210,100 4,202,000 SH   SOLE   4,202,000 0 0
MERSANA THERAPEUTICS INC. COM 59045L106 5,925 3,750,000 SH   SOLE   3,750,000 0 0
MIRATI THERAPEUTICS INC. COM 60468T105 77 1,000 SH   SOLE   1,000 0 0
PUMA BIOTECHNOLOGY INC. COM 74587V107 15,254 1,417,000 SH   SOLE   1,417,000 0 0
REGULUS THERAPEUTICS INC COM NEW 75915K200 1,333 1,851,851 SH   SOLE   1,851,851 0 0